These findings are significant because increased estrogen signaling has been demonstrated to be a risk factor for developing ERα+ breast tumors; therefore, understanding the molecular mechanisms that govern ERα and estrogen signaling in healthy breast cells provides insights into how alterations to this signaling axis may lead to the development of premalignant lesions. This evidence concerns the gene ESR1 and breast neoplasm.